Market closedNon-fractional
Corcept Therapeutics/CORT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Ticker
CORT
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Menlo Park, United States
Employees
352
Website
www.corcept.com
CORT Metrics
BasicAdvanced
$3.6B
Market cap
33.07
P/E ratio
$1.05
EPS
0.44
Beta
-
Dividend rate
Price and volume
Market cap
$3.6B
Beta
0.44
Financial strength
Current ratio
5.179
Quick ratio
4.879
Total debt to equity
0.014
Management effectiveness
Return on assets (TTM)
11.97%
Return on equity (TTM)
21.91%
Valuation
Price to earnings (TTM)
33.074
Price to revenue (TTM)
6.813
Price to book
6.63
Price to tangible book (TTM)
6.63
Price to free cash flow (TTM)
28.603
Growth
Revenue change (TTM)
26.51%
Earnings per share change (TTM)
30.12%
3-year revenue growth (CAGR)
15.47%
3-year earnings per share growth (CAGR)
10.56%
What the Analysts think about CORT
Analyst Ratings
Majority rating from 5 analysts.
CORT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$147M
8.42%
Net income
$28M
-11.50%
Profit margin
18.86%
-18.39%
CORT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.25
$0.28
$0.28
$0.25
-
Expected
$0.15
$0.22
$0.26
$0.22
$0.23
Surprise
66.67%
28.24%
8.53%
13.64%
-
CORT News
AllArticlesVideos
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
GlobeNewsWire·4 days ago
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions
GlobeNewsWire·1 month ago
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corcept Therapeutics stock?
Corcept Therapeutics (CORT) has a market cap of $3.6B as of July 26, 2024.
What is the P/E ratio for Corcept Therapeutics stock?
The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 33.07 as of July 26, 2024.
Does Corcept Therapeutics stock pay dividends?
No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Corcept Therapeutics dividend payment date?
Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Corcept Therapeutics?
Corcept Therapeutics (CORT) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Corcept Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.